EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Palbociclib as an Antitumor Drug: A License to Kill

Agnieszka Łupicka-Słowik iD, Federica Cossu iD, Marcin Sieńczyk iD

Molecules · 13.11.2024 · 29 (22) · 5334

DOI: 10.3390/molecules29225334 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 13.11.2024. Verfasst von Agnieszka Łupicka-Słowik und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wybrzeze Wyspianskiego 27, 50-370 Wr…. Hauptthemen laut MEDLINE: Pyridines, Piperazines, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wroclaw University of Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoplastic cells are characterized by uncontrolled cell divisions caused by cell cycle dysregulation. Key regulatory proteins governing the transition from the G1 to the S phase are the CDK4 and CDK6 kinases, which are controlled by D-type cyclins. The CDK4/6 kinases enable the use of these proteins as targets for anticancer therapy because they prevent the growth and the development of malignant cells by inhibiting their activity. This paper surveys the clinical trial results concerning palbociclib, the first in-class FDA-approved anticancer drug for hormone-dependent breast cancer. It discusses the therapeutic applications in breast cancer as well as in solid tumors and hematopoietic malignancies. Additionally, the paper presents an analysis of palbociclib resistance acquired during therapy and explores new approaches, such as modifications to palbociclib that enhance its desired activity or open up new therapeutic possibilities (PROTACs).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridinesPiperazinesAntineoplastic AgentsHumansCyclin-Dependent Kinase 6Protein Kinase InhibitorsBreast NeoplasmsCyclin-Dependent Kinase 4Drug Resistance, NeoplasmClinical Trials as TopicFemale

Stichwörter der Autor:innen

PROTACSNIPERSTNBCantitumorcyclin-dependent kinasespalbociclibtargeted therapy

Substanzen

palbociclibPyridinesPiperazinesAntineoplastic AgentsCyclin-Dependent Kinase 6Protein Kinase InhibitorsCyclin-Dependent Kinase 4

Autor:innen und Institutionen

  • Division of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wybrzeze Wyspianskiego 27, 50-370 Wroclaw, Poland.
  • National Research Council, Institute of Biophysics (IBF-CNR), Milan Unit, Via Corti, 12, 20133 Milan, Italy.

ORCID-Profile: Agnieszka Łupicka-Słowik, Federica Cossu, Marcin Sieńczyk

Förderung

  • Wroclaw University of Technology

Zitieren

APA

Łupicka-Słowik, A., Cossu, F., & Sieńczyk, M. (2024). Palbociclib as an Antitumor Drug: A License to Kill. Molecules, 29(22), 5334. https://doi.org/10.3390/molecules29225334

Vancouver

Łupicka-Słowik A, Cossu F, Sieńczyk M. Palbociclib as an Antitumor Drug: A License to Kill. Molecules. 2024;29(22):5334. doi:10.3390/molecules29225334

BibTeX
@article{upickaSowik2024,
  author = {Łupicka-Słowik, Agnieszka and Cossu, Federica and Sieńczyk, Marcin},
  title = {Palbociclib as an Antitumor Drug: A License to Kill},
  journal = {Molecules},
  year = {2024},
  volume = {29},
  number = {22},
  pages = {5334},
  doi = {10.3390/molecules29225334}
}
Kostenlos starten →